AARDS Pioneers Breakthrough Device for Rheumatoid Arthritis Treatment
AARDS Research Leads in Rheumatoid Arthritis Treatment Innovation
AARDS Research, recognized for its exceptional contributions to arthritis treatment, has achieved a remarkable milestone recently. With the FDA's approval of The SetPoint System, AARDS becomes a beacon of hope for those suffering from rheumatoid arthritis (RA). Dr. Norman B. Gaylis, serving as the Medical Director, has become the first physician in the country to implant this advanced device. This marks a significant leap forward in the bioelectronics field, offering relief to over 1.5 million individuals impacted by RA.
Breaking New Ground with SetPoint Technology
Dr. Gaylis expressed his enthusiasm for the FDA's acknowledgment of this technology's effectiveness. "We are privileged to be the first clinic to administer the SetPoint implant," he stated. This innovative approach initiates a new chapter in RA management by utilizing an implant placed in the neck to stimulate the vagus nerve. This daily stimulation is designed to lessen the inflammation that contributes to the life-altering symptoms of RA.
Patient Success Stories
Among the recipients of this groundbreaking treatment is Gerline Brutus, who began her journey with Dr. Gaylis after years of ineffective medication. She shared her transformative experience, stating, "I struggled immensely; daily tasks felt insurmountable. Now, I thrive again, indulging in activities like exercise and cycling that I had long abandoned," reflecting on her restored independence.
The SetPoint System: A Game Changer in Autoimmune Therapy
The FDA’s approval of The SetPoint System is a watershed moment, heralding a new era in autoimmune disease treatment. This device is positioned to alter how conditions like lupus, Crohn's disease, multiple sclerosis, and inflammatory bowel disease are approached in clinical settings. Dr. Gaylis highlighted the potential of this technology, emphasizing a fundamental shift from traditional RA treatments that often compromise the immune system. "By resetting the immune response rather than simply suppressing it, we've seen no adverse effects among our patients," he noted.
Expanding the Clinical Landscape
The pioneering decision to employ The SetPoint device is not just a benefit for current RA patients; it signifies a broader potential for clinical innovation. With more trials set to commence for other autoimmune diseases, AARDS Research is expanding its role in developing effective therapies that offer hope to those who feel their options are exhausted.
AARDS Research: A Legacy of Excellence
With over 40 years of clinical research experience, AARDS Research stands at the forefront of medical discovery. They have participated in comprehensive clinical trials that have led to over 150 FDA-approved therapies, continuously striving to deliver hope and care to patients with chronic illnesses. Their mission reflects a commitment to patient-centered innovations that prioritize the well-being of individuals suffering from complex conditions.
Dr. Norman B. Gaylis: A Dedicated Leader in Rheumatology
Dr. Gaylis is not just a physician; he is a leader recognized for his exceptional contributions to the field of rheumatology. His expertise and advocacy have shaped advances in patient care. In addition to his clinical work, he actively participates in ongoing research and education within the American College of Rheumatology. His establishment of the Norman B. Gaylis, MD Research Award exemplifies his dedication to supporting research that elevates clinical practices.
Frequently Asked Questions
What is The SetPoint System?
The SetPoint System is a newly approved implantable device aimed at treating rheumatoid arthritis by stimulating the vagus nerve to reduce inflammation.
Who is Dr. Norman B. Gaylis?
Dr. Gaylis is the Medical Director at AARDS Research and the first U.S. physician to implant The SetPoint device.
How does the SetPoint device work?
The device is surgically implanted in the neck and activates the vagus nerve, which helps modulate the immune response and reduce RA symptoms.
What conditions is AARDS Research focused on?
AARDS Research specializes in autoimmune disorders, including rheumatoid arthritis, lupus, and Crohn's disease, and is expanding its research into other conditions.
How can patients learn more about their research?
Patients can inquire about clinical trials and treatments by contacting AARDS Research or visiting their website to get up-to-date information on ongoing studies.
About The Author
Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
